CRISPR Therapeutics
CRSP
406 hedge funds and large institutions have $2.5B invested in CRISPR Therapeutics in 2023 Q3 according to their latest regulatory filings, with 45 funds opening new positions, 155 increasing their positions, 101 reducing their positions, and 53 closing their positions.
53% more repeat investments, than reductions
Existing positions increased: 155 | Existing positions reduced: 101
0.32% less ownership
Funds ownership: 69.41% → 69.09% (-0.32%)
3% less funds holding
Funds holding: 418 → 406 (-12)
12% less call options, than puts
Call options by funds: $80.5M | Put options by funds: $91.5M
15% less first-time investments, than exits
New positions opened: 45 | Existing positions closed: 53
19% less capital invested
Capital invested by funds: $3.07B → $2.5B (-$575M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$15.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$13M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$10.2M |
| 4 |
IHAM
Integral Health Asset Management
New York
|
+$9.04M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$8.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$16.6M |
| 2 |
VCM
Valiant Capital Management
San Francisco,
California
|
-$12.9M |
| 3 |
Two Sigma Investments
New York
|
-$11M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$9.06M |
| 5 |
Renaissance Technologies
New York
|
-$7.47M |
CRSP Hedge Fund Activity: Q3 2023 in Review
406 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q3 2023, worth a combined $2.5B — down 19% from $3.07B a quarter earlier.
Sellers outnumbered buyers: 53 funds closed out of CRSP and 45 opened new positions — a net loss of 8 holders — while 101 trimmed existing stakes and 155 added.
The largest buyer was Westfield Capital Management, opening a new position worth an estimated $15.4M. The largest seller was Marshall Wace, cutting an estimated $16.6M.
- 406 institutional investors held CRISPR Therapeutics (CRSP) as of Q3 2023, down from 418 in Q2 2023.
- Funds reported $2.5B of CRISPR Therapeutics stock for Q3 2023, down 19% quarter-over-quarter.
- 45 funds opened new CRISPR Therapeutics positions in Q3 2023 and 53 closed out, a net change of -8 holders.
- The largest CRISPR Therapeutics buyer in Q3 2023 was Westfield Capital Management, an estimated $15.4M added.
- The largest CRISPR Therapeutics seller in Q3 2023 was Marshall Wace, an estimated $16.6M sold.
Based on aggregated 13F filings for Q3 2023.